《藍籌業績》中生製藥(01177.HK)首季純利19.13億人幣升118.5% 季度息維持2港仙
中國生物製藥(01177.HK)公布截至今年3月底止首季業績,收入錄72.43億元人民幣(下同),按年升16.4%。純利19.13億元,按年升118.5%;每股盈利10.19分。派季度息2港仙,按年持平。
首季收入中,有約47.3%來自新產品銷售,達到34.33億元,按年升67%。以治療領域劃分,抗腫瘤用藥銷售額達約26.38億元,較去年同期上升約31.8%,佔收入約36.4%;肝病用藥銷售額達9.45億元,佔收入比重13.1%。
首季中生製藥新獲得臨床批件7件、生產批件7件及一致性評價獲批12件、申報臨床8件、一致性評價申報4件及申報生產2件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.